Figure 4 from Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models

Résumé fourni par la source

Longitudinal analysis demonstrates that PAT can be used to indicate survival benefit from bevacizumab therapy. A and B, Oxygenation (SO2MSOT) and normalized hemoglobin content (THb) increase from enrollment (noted as “pre”) to endpoint of tumor excision (noted as “post”) in the Ctrl group (A), while in the Bev-NR group (B), SO2MSOT increases concurrently with a decrease in normalized THb. C, Conversely, the Bev-R group trend toward a significant decrease in SO2MSOT, with no significant change in normalized THb observed. D, Estimated SO2MSOT level as a function of time (number of days from enrollment) and group (color). Trendlines are shown alone for clarity; individual tumor trajectories are shown in Supplementary Fig. S5. Ctrl tumor data parallel Bev-NR data. Analysis of SO2MSOT over time during the study showed a significant (P < 0.0001) change in slope at 3 weeks after enrollment in the Bev-R group compared with either of the Ctrl or Bev-NR groups. Ctrl, ntumors = 14 and nmice = 8; Bev-NR, ntumors = 14 and nmice = 8; Bev-R, ntumors = 6 and nmice = 3. P values are displayed from two-sided paired Student t tests; shaded areas in D denote the 95% pointwise confidence bounds for the average.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.